Amphastar FDA Wins And Pipeline Expansion Contrast With Weak Earnings And Valuation [Yahoo! Finance]
Amphastar Pharmaceuticals, Inc. (AMPH)
Last amphastar pharmaceuticals, inc. earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amphastar.com/investor-relations
Company Research
Source: Yahoo! Finance
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Amphastar Pharmaceuticals (NasdaqGS:AMPH) received FDA approvals for iron sucrose and teriparatide injections. The company also secured FDA approval for ipratropium bromide HFA inhalation aerosol with 180-day generic exclusivity. Management is expanding a proprietary pipeline in oncology, ophthalmology, and immunology, including novel peptides and a synthetic corticotropin compound. These developments arrive after a period of earnings disappointment and share price weakness. Amphastar Pharmaceuticals, trading around $20.23 per share, has seen its stock under pressure, with a 29.1% decline over the past week and a 23.5% decline year to date. Over the past 3 years, the stock is down 44.0%, while the 5 year return stands at 15.5%, creating a mixed backdrop for the latest product and pipeline updates. For investors watching NasdaqGS:AMPH, the combination of fresh FDA ap
Show less
Read more
Impact Snapshot
Event Time:
AMPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMPH alerts
High impacting Amphastar Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AMPH
News
- Wells Fargo Sees Amphastar Pharmaceuticals, Inc.'s (AMPH) AMP-007 as Key to Mid- to High-Single-Digit Growth [Yahoo! Finance]Yahoo! Finance
- Amphastar: Higher Costs, Lower Growth, And A 'Value Trap' Label [Seeking Alpha]Seeking Alpha
- Why Amphastar Pharmaceuticals (AMPH) Shares Are Plunging Today [Yahoo! Finance]Yahoo! Finance
- Amphastar Pharmaceuticals (AMPH) had its price target lowered by Wells Fargo & Company from $34.00 to $30.00. They now have an "overweight" rating on the stock.MarketBeat
- Amphastar Pharmaceuticals (AMPH) had its price target lowered by Needham & Company LLC from $34.00 to $30.00. They now have a "buy" rating on the stock.MarketBeat
AMPH
Earnings
- 2/26/26 - Miss
AMPH
Sec Filings
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- 1/12/26 - Form 8-K
- AMPH's page on the SEC website